Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Relative Bioavailability Study of HNC364 Following Intramuscular Injections vs. AZILECT® (Rasagiline Tablet) Following Oral Administration at the Steady-State in Healthy Adult Subjects

NCT06798519 is registered in ClinicalTrials.gov with Guangzhou Henovcom Bioscience Co. Ltd. as lead sponsor.

NCT NCT06798519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06798519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Relative Bioavailability Study of HNC364 Following Intramuscular Injections vs. AZILECT® (Rasagiline Tablet) Following Oral Administration at the Steady-State in Healthy Adult Subjects
Lead sponsor
Guangzhou Henovcom Bioscience Co. Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 8, 2026
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd)